Larvol Delta - shibio-Doses-First-Patient-in-Phase-1b-Trial-of-Andecaliximab-in-Patients-with-Spinal-Cord-Injury-SCI-at-Risk-of-Heterotopic-Ossification-HO

andecaliximab (GS-5745) - āshibio

https://www.businesswire.com/news/home/20250610649423/en/shibio-Doses-First-Patient-in-Phase-1b-Trial-of-Andecaliximab-in-Patients-with-Spinal-Cord-Injury-SCI-at-Risk-of-Heterotopic-Ossification-HO

Jun 24, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next